OncoMyx Therapeutics
Phoenix
About OncoMyx Therapeutics
OncoMyx Therapeutics develops oncolytic immunotherapies called myxoma (MYXV) to assist in creating an immune response and treat cancer. Its myxoma virus (MYXV) platform targets hematologic and solid tumors with a unique oncolytic virus called myxoma and a novel patented systemic delivery approach which can be carried systemically by human leukocytes where it can then infect tumor cells. The company was founded in 2018 and is headquartered in Phoenix, Arizona.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $50.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2021)
- Website: oncomyx.com
Industries & Categories
Biotechnology, Health Diagnostics, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/oncomyx-therapeutics-89134 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.